Market News & Trends
Catalent Expands Nasal Drug Development & Manufacturing Capabilities at North Carolina Facility
Catalent recently announced it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP), North Carolina, facility, to…
Copley Launches New Semi-Automation Tool for Inhaled Product Testing
Copley Scientific, the global leader in inhaled product testing equipment, has launched the new Gentle Rocker 100i, a simple, cost-effective device that boosts the productivity and repeatability of….
QSAM Biosciences Doses First Patient in its Clinical Trial for Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
QSAM Biosciences Inc. recently announced the first patient commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. QSAM previously announced…
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement With CMAX Clinical Research
Skye Bioscience, Inc. recently retained CMAX Clinical Research to facilitate enrollment of and drug administration to healthy volunteers for Skye’s Phase 1 study of its…
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA in Adult Patients With Metastatic, Hormone-Refractory Breast Cancer
HiberCell recently announced the first patients have been dosed in a Phase 2 clinical trial of odetiglucan plus KEYTRUDA (pembrolizumab) for the treatment of metastatic,…
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Vaxxinity, Inc. recently announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s…
Caladrius Biosciences & Cend Therapeutics Announce Definitive Merger Agreement
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. recently announced the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of….
Symeres Acquires Organix, Adding Lipids Expertise & Strategic Foothold in the US
Symeres recently announced the acquisition of Organix Inc., a US-based specialized organic chemistry services provider with a focus on lipids…..
SOTIO Initiates CLAUDIO-01 Trial With Antibody-Drug Conjugate SOT102 in Patients With Gastric & Pancreatic Cancer
SOTIO Biotech recently announced it has dosed the first patient in its Phase 1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. SOT102 is the lead program of….
First European Union Patient Dosed With 177Lu-PNT2002 in the Phase 3 SPLASH Trial
POINT Biopharma Global Inc. recently announced the first patient in the European Union (EU) has been dosed in the Phase 3 SPLASH trial (NCT04647526). The SPLASH trial….
Prothena Receives FDA Fast Track Designation for Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease
Prothena Corporation plc recently announced the US FDA has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody therapy currently being…
GeoVax Announces Issuance of Malaria Vaccine Patent
GeoVax Labs, Inc. recently announced the US Patent and Trademark Office has issued Patent No. 11,311,612 to GeoVax, pursuant to the company’s patent application No.…
Editas Medicine Receives FDA Rare Pediatric Disease Designation for the Treatment of Beta Thalassemia
Editas Medicine, Inc. recently announced US FDA granted Rare Pediatric Disease designation to EDIT-301, an investigational, gene-edited medicine for the treatment of beta thalassemia. The…
Taconic Biosciences & Biomodels Establish Microbiome Initiative
Taconic Biosciences and Biomodels have recently launched the Taconic-Biomodels Microbiome Initiative (TBMI), providing investigators with seamless access to complete germ-free and gnotobiotic microbiome study solutions, from design to data….
Sol-Gel Technologies & Galderma Announce FDA Approves First Topical Rosacea Treatment With Microencapsulated BPO
Sol-Gel Technologies, Ltd. recently announced the Food and Drug Administration (FDA) approval of its drug product, EPSOLAY, a proprietary cream formulation of….
Catalent Acquires Commercial-Scale Cell Therapy Development & Manufacturing Facility From Erytech
Catalent recently announced it has acquired from Erytech Pharma its state-of-the-art, commercial-scale cell therapy manufacturing facility in Princeton, NJ, for $44.5 million. The deal includes…
Starton Therapeutics Doses First Subjects in Phase 1 Clinical Trial of STAR-LLD Continuous Delivery Lenalidomide
Starton Therapeutics Inc. recently announced it has dosed the first subjects in a first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide,…
Priothera Receives FDA Clearance of IND to start Phase 2b/3 Study With Mocravimod in AML Patients Undergoing Allogeneic HSCT
Priothera Ltd recently announced the US FDA has provided clearance to proceed with the company's Investigational New Drug (IND) application to begin its pivotal Phase…
Lonza Early Development Services & Integral Molecular to Offer Complementary Expertise to Enhance Early De-Risking of Biotherapeutics
Lonza and Integral Molecular recently announced a strategy to offer complementary expertise to their respective customers to better assess the risks of off-target binding of…
Blacktrace Launches Particle Works – The New Dedicated Particle Engineering Brand
Particle Works’ game-changing particle engineering platforms are set to revolutionize the way customers discover, develop and scale-up particle production for a wide range of….
